Endothelin-converting enzyme can hydrolyze the vasodilator bradykinin, indicating a broader substrate specificity that may inform the design of new ECE inhibitors.
Answers are grounded in this paper and cite their sources.
Extends ECE substrate specificity in vitro; leaves open cardiovascular effects of bradykinin hydrolysis and inhibitor design.
Endothelin-converting enzyme (ECE) is the key enzyme in the production of the potent vasoconstrictor endothelin from its inactive precursor big endothelin. To date, no other physiological peptide substrate has been identified for ECE. Here, by using Chinese hamster ovary (CHO) cells transfected with rat ECE-1 cDNA, we have established that ECE can hydrolyse the vasodilator bradykinin. The hydrolysis of bradykinin by ECE is exclusively at the Pro7-Phe8 bond, producing bradykinin-(1-7) and bradykinin-(8-9). Hydrolysis is completely inhibited by 100 microM phosphoramidon and 200 microM EDTA, but only slightly by the specific neprilysin inhibitor thiorphan (100 microM). The ability of ECE to act as a peptidyl dipeptidase rather than an endopeptidase in hydrolysing bradykinin suggests a much broader specificity for the enzyme than previously recognized, which may lead to the design of new and specific inhibitors of ECE and to the identification of other potential physiological substrates.
No takes yet. Share an insight, caveat, or question.
Hoang et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: